Immuron’s proprietary technology is based on generating hyper-immune bovine colostrum that is rich in polyclonal antibodies also known as immunoglobulins. The major advantages of Immuron technology are the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine antibodies can withstand the acidic environment of the stomach and are resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine antibodies also possess the unique ability to remain active in the human GI tract where they target enteric pathogens. The underlying nature of our platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to generate bovine antibodies that block viruses or bacteria at mucosal surfaces in the Gastrointestinal tract and neutralize the toxins they produce. Additionally, the dairy origins of our antibodies have enabled us to commercialize our flagship product Travelan® via regulatory pathways, including prescription (Rx), medical foods, over-the-counter medicines, and dietary supplements.